Benzinga | May 21, 2021 09:04AM EDT

JP Morgan Upgrades ResMed to Overweight, Raises Price Target to $219

JP Morgan analyst David Low upgrades ResMed (NYSE:RMD) from Neutral to Overweight and raises the price target from $206 to $219.